Table 1. Significant differences in phosphoprotein changes between tumor types.
| Drug (target) | NSCLC vs CRC + PDAC | CRC vs NSCLC + PDAC | PDAC vs NSCLC + CRC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Increased | Not increased | Decreased | Not decreased | Increased | Not increased | Decreased | Not decreased | Increased | Not increased | Decreased | Not decreased | |
| AZD5363 (AKT) | RB | IR SRC |
STAT5 | IR | ||||||||
| Everolimus (m-TOR) | SRC S6K |
MEK | RB | C-MET IRS1 | ||||||||
| Gefitinib (EGFR) | m-TOR | IRS1 | ||||||||||
| Luminespib (HSP90) | MEK | PTEN | IGF1R IRS1 |
B-Catenin | C-KIT | |||||||
| Pictilisib (PI3K) | m-TOR MEK |
CHK1 CHK2 PTEN |
GSK3B | PRAS40 AKT |
||||||||
| Trametinib (MEK) | PDGFRB SRC |
B-Catenin CHK2 |
||||||||||
| Vemurafenib (KRAS) | FGFR1 HER3 IR STAT5 |
m-TOR | CHK1 | PRAS40 C-KIT |
||||||||
Changes in phosphorylation of proteins that were increased or decreased upon exposure to different drugs but were significantly different from cells derived from different tumor types i.e. NSCLC, CRC and PDAC upon logistic regression corrected for multiple testing.